Healthcare Services company Krsnaa Diagnostics announced Q2FY26 results Revenue from Operations: Rs 2,060 million compared to Rs 1,863 million during Q2FY25, change 11%. EBITDA: Rs 602 million compared to Rs 509 million during Q2FY25, change 18%. EBITDA Margin: 29% for Q2FY26. PAT: Rs 239 million compared to Rs 196 million during Q2FY25, change 22%. PAT Margin: 12% for Q2FY26. EPS: Rs 7.25 for Q2FY26. Yash Mutha, Managing Director, said: “Krsnaa Diagnostics has delivered its highest-ever quarterly profit, reinforcing the strength and resilience of our business model. Revenue grew 12% YoY in H1FY26, driven by expanding patient volumes and the growing confidence in our diagnostic network across India. EBITDA increased 18% YoY to Rs 1,126 million, with margins improving to 28%, reflecting disciplined execution and strong operating leverage. Net profit rose 19% to Rs 445 million, underscoring our focus on profitable and sustainable growth. Over the years, we have built one of India’s most efficient and inclusive diagnostic platforms, with a presence across Tier-II and Tier-III markets through our Public-Private Partnership model. This structure not only supports volume growth but also provides stability through long-term contracts and broad geographic diversification. On the working capital side, our receivable cycle currently stands around 150+ days, reflecting a temporary transition linked to new central government payment norms under which states are aligning to RBI-linked disbursement mechanisms. Furthermore, Krsnaa has not recorded any bad debts since inception, underscoring the quality of our receivables and the credibility of our government partnerships. Our focus remains on accelerating collections, optimizing cash flows, and reinvesting into high-impact growth initiatives such as the Rajasthan PPP — India’s largest diagnostic project — which is progressing well and on schedule. With multiple labs going live in the coming months, we anticipate meaningful revenue contribution starting Q4FY26 and a full-year impact in FY27. With strong fundamentals, disciplined execution, and a clear growth roadmap, Krsnaa is well-positioned to deliver sustainable value and reinforce its leadership in India’s diagnostics landscape.” Pallavi Bhatevara, Executive Director, said: “At Krsnaa Diagnostics, we remain steadfast in our commitment to quality, integrity, and patient-centric care. Leveraging our Public-Private Partnership (PPP) model, we provide free and high-quality diagnostic services across India, enabling millions to access essential healthcare. Our pan-India network and close collaboration with state governments have firmly established Krsnaa as a trusted and preferred partner in public healthcare delivery. We are delighted to announce that for the first time in India, our company has received accreditation from the American College of Radiology (ACR) — a prestigious milestone marking the first-ever ACR recognition outside the United States. This global distinction stands as a testament to Krsnaa’s unwavering pursuit of excellence and adherence to international standards in imaging and radiology. Additionally, we are also proud to continue holding the CAP (College of American Pathologists) accreditation, the only such recognition granted to a government diagnostic location in India. These dual international accreditations underscore our relentless focus on quality, precision, and patient safety. They reaffirm Krsnaa’s position as a benchmark for globally recognized diagnostic standards in India, strengthening our reputation among clinicians, government partners, and patients alike. Importantly, these achievements also contribute to higher patient trust, improved volumes, and stronger institutional credibility, supporting long-term growth. Recently, we were honoured with the title of “India’s Most Trusted Integrated Diagnostic Brand” at the Big FM – Big Impact Awards held in Vietnam, a testament to our unwavering commitment to quality, accessibility, and patient trust With a foundation built on internationally accredited quality, a scalable nationwide platform, and a clear mission to make advanced diagnostics accessible to all, Krsnaa Diagnostics is well-positioned to capitalize on India’s expanding healthcare landscape, drive sustainable growth, and enhance value for all stakeholders.” Result PDF